Autor segons l'article: Sepulveda, Maria; Martinez-Hernandez, Eugenia; Gaba, Lydia; Victoria, Ivan; Sola-Valls, Nuria; Falgas, Neus; Casanova-Molla, Jordi; Graus, Francesc;
Departament: Medicina i Cirurgia
Autor/s de la URV: Casanova Mollà, Jordi
Paraules clau: Toxic neuropathy Therapy Polyradiculoneuropathy Pembrolizumab Patient Nivolumab Myasthenia-gravis Multiple-sclerosis Ipilimumab treatment Immune neuropathy Guillain-barre-syndrome Cns demyelination Checkpoint Cancer Anti-programmed death-1 receptor
Resum: IntroductionPembrolizumab, a monoclonal antibody directed against the immune checkpoint programmed cell death-1 receptor (PD-1), has improved survival in patients with advanced melanoma. Neuromuscular immune-mediated side effects have been rarely reported.MethodsWe describe a 44-year-old man with metastatic melanoma who presented with progressive muscle weakness after 23 doses of pembrolizumab.ResultsThe patient developed asymmetric, proximal muscle weakness and atrophy in all four limbs. Cerebrospinal fluid examination showed albuminocytologic dissociation. MRI revealed contrast enhancement of the lumbosacral roots. Electrodiagnostic studies demonstrated widespread fibrillation potentials in all four limbs, suggesting a generalized motor polyradiculopathy. Despite pembrolizumab discontinuation and treatment with steroids and intravenous immunoglobulin, limb weakness worsened. Electrodiagnostic studies were repeated, and showed marked and diffuse axonal motor damage. Seven weeks after clinical onset the patient was treated with plasma exchanges. He showed no further deterioration.DiscussionWe report a severe motor polyradiculopathy associated with an anti-PD-1 agent that expands the spectrum of neuromuscular complications of this class of drugs. Muscle Nerve56: E162-E167, 2017
Àrees temàtiques: Saúde coletiva Physiology (medical) Physiology Odontología Nutrição Neurosciences Neurology (clinical) Medicina veterinaria Medicina iii Medicina ii Medicina i Interdisciplinar General medicine Farmacia Ensino Engenharias iv Engenharias iii Engenharias ii Educação física Educação Clinical neurology Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Cellular and molecular neuroscience Biotecnología
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: jordi.casanova@urv.cat
Identificador de l'autor: 0000-0003-0565-8015
Data d'alta del registre: 2024-09-07
Versió de l'article dipositat: info:eu-repo/semantics/acceptedVersion
Enllaç font original: https://onlinelibrary.wiley.com/doi/epdf/10.1002/mus.25672
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Muscle & Nerve. 56 (6): E162-E167
Referència de l'ítem segons les normes APA: Sepulveda, Maria; Martinez-Hernandez, Eugenia; Gaba, Lydia; Victoria, Ivan; Sola-Valls, Nuria; Falgas, Neus; Casanova-Molla, Jordi; Graus, Francesc; (2017). Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma. Muscle & Nerve, 56(6), E162-E167. DOI: 10.1002/mus.25672
DOI de l'article: 10.1002/mus.25672
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2017
Tipus de publicació: Journal Publications
Repositori URV